NDLI: Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.

Please wait, while we are loading the content...

Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients.

Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women.

The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study).

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.

PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: baseline health and healthcare utilization of the US sample.

Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.

Fatty acid synthase inhibitor, C75, blocks resistin-induced increases in lipid accumulation by human macrophages.

Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety.

Year: 2008 Volume: 10 Issue: 11

Year: 2008 Volume: 10 Issue: 10

Year: 2008 Volume: 10 Issue: 9

Year: 2008 Volume: 10 Issue: 8

Year: 2008 Volume: 10 Issue: 7

Year: 2008 Volume: 10 Issue: 6

Year: 2008 Volume: 10 Issue: 5

Year: 2008 Volume: 10 Issue: 4

Year: 2008 Volume: 10 Issue: Supplementary 4

Year: 2008 Volume: 10 Issue: 3

Year: 2008 Volume: 10 Issue: 2

Year: 2008 Volume: 10 Issue: Supplementary 2

Year: 2008 Volume: 10 Issue: Supplementary 1

Year: 2007 Volume: 9

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Mannucci, E. Monami, M. Lamanna, C. Gensini, G. F. Marchionni, N.
Description	Country affiliation: Italy Author Affiliation: Mannucci E ( Department of Cardiovascular Medicine, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy. edoardo.mannucci@unifi.it)
Abstract	AIM: The aim of this meta-analysis of randomized clinical trials (RCT) was to assess whether pioglitazone is also associated with increased cardiovascular risk, as recently reported for rosiglitazone. METHODS: RCT of pioglitazone were retrieved from Medline (any date up to 31 August 2007; English language only). Unpublished RCT were identified through http://www.clinicaltrials.gov or http://www.fda.gov websites, and results on cardiovascular outcomes were retrieved from investigators and/or sponsors, whenever possible. RCT were included in meta-analysis if pioglitazone was compared with other treatments (placebo, active comparators or no treatment) for at least 4 weeks. Ninety-four trials, 10 of which were unpublished, were retrieved; those included in the analysis, which excluded PROspective PioglitAzone Clinical Trial In MacroVascular Events (PROACTIVE), enrolled 11 268 and 9912 patients in the pioglitazone and comparator groups respectively. Data for analysis, extracted independently by two observers, included all-cause and cardiovascular mortality and incidence of non-fatal coronary events and heart failure. Proportions of outcome measures across treatment groups were compared by odds ratios (ORs) and 95% confidence interval. RESULTS: Pioglitazone was associated with reduced all-cause mortality [OR 0.30 (0.14-0.63); p < 0.05], with no relevant effect on non-fatal coronary events. The observed increase in incidence of non-fatal heart failure was not statistically significant [OR 1.38 (0.90-2.12)]. CONCLUSION: The use of pioglitazone does not appear to be harmful in terms of cardiovascular events and all-cause deaths.
File Format	HTM / HTML
ISSN	14628902
Issue Number	12
Volume Number	10
e-ISSN	14631326
Journal	Diabetes, Obesity and Metabolism
Language	English
Publisher	Wiley-Blackwell
Publisher Date	2008-12-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Metabolism Discipline Endocrinology Discipline Pharmacology Discipline Diabetology Coronary Disease Chemically Induced Diabetes Mellitus, Type 2 Drug Therapy Heart Failure Hypoglycemic Agents Adverse Effects Thiazolidinediones Aged Cause Of Death Mortality Prevention & Control Humans Middle Aged Randomized Controlled Trials As Topic Risk Factors Treatment Outcome Comparative Study Journal Article Meta-analysis Review
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism Internal Medicine Endocrinology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Type 2 diabetes, thiazolidinediones, and cardiovascular risk.

Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?

Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.

Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.

Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.

Similar Documents

Type 2 diabetes, thiazolidinediones, and cardiovascular risk.

Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?

Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.

Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.

Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.